Dose-response relationship of insulin glulisine in subjects with type 1 diabetes

Diabetes, Obesity and Metabolism

Volumn 11, Issue 1, 2009, Pages 60-68

  Becker, Reinhard H A ^a   Frick, A D ^a   Teichert, L ^a   Nosek, L ^b   Heinemann, L ^b   Rave, K ^b  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b Profil Institute for Metabolic Research   (Germany)

Author keywords

Dose response proportionality; Euglycaemic glucose clamp; Insulin analogues; Insulin glulisine; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLULISINE; INSUMAN RAPID U100; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG METABOLISM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; OUTCOME ASSESSMENT; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL;

EID: 58149197775     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.01013.x     Document Type: Article

References (30)

1. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999; 42: 1151-1167.
2. Hirsch IB, Insulin analogues. N Engl J Med 2005; 352: 174-183.
3. Leiter LA, Ceriello A, Davidson JA et al. Postprandial glucose regulation: New data and new implications. Clin Ther 2005; 27: S42-S56.
4. Home P. Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 2005; 21: 989-998.
5. Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract 2006; 12: 42-46.
6. Hennige AM, Kellerer M, Strack V et al. New human insulin analogs: characteristics of insulin signaling in comparison to AspB10 and regular insulin. Diabetologia 1999; 42: A178.
7. Richards JP, Stickelmeyer MP, Flora DB et al. Self-association properties of monomeric insulin analogs under formulation conditions. Pharm Res 1998; 15: 1434-1441.
8. Zoete V, Meuwly M, Karplus M. Study of the insulin dimerization: Binding free energy calculations and per-residue free energy decomposition. Proteins 2005; 61: 79-93.
9. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.
10. Bakaysa DL, Radziuk J, Havel HA et al. Physicochemical basis for the rapid time-action of LysB28ProB29-insulin: Dissociation of a protein-ligand complex. Protein Sci 1996; 5: 2521-2531.
11. Aspart I 2000. http://www.fda.gov/cder/foi/label/2000/20986lbl.pdf. Accessed September 2008.
12. Becker R, Frick A, Wessels D, Scholtz H. Evaluation of the pharmacodynamic and pharmacokinetic profiles of insulin glulisine - a novel, rapid-acting, human insulin analogue. Diabetologia 2003; 46: A775.
13. Becker R, Frick A, Wessels D, Scholtz H. Pharmacodynamics and pharmacokinetics of a new, rapidly acting insulin analogue, insulin glulisine. Diabetes 2003; 52: A471.
14. Frick A, Becker RH, Wessels DH, Scholtz HE. Pharmacokinetic and glucodynamic profiles of insulin glulisine: An evaluation following subcutaneous administration at various injection sites. Diabetologia 2003; 46: A776.
15. Garg SK, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: Insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract 2005; 11: 11-17.
16. Hermansen K, Fontaine P, Kukolja KK et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47: 622-629.
17. Woodworth J, Howey D, Bowsher R et al. [Lys (B28), Pro (829)] human insulin(K): Dose-ranging vs. humulin R (H). Diabetes 1993; 42: 54A.
18. Heinemann L, Woodworth JR. Pharmacokinetics and glucodynamics of insulin lispro. Drugs Today 1998; 34: 23-36.
19. Lindholm A, Sasaki T, Edwards A, Hedge A. Dose dependency in absorption of insulin aspart in healthy Caucasians and Japanese. Diabetes 2001; 50: A441.
20. Kaku K, Matsuda M, Urae A, Irie S. Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. Diabetes Res Clin Pract 2000; 49: 119-126.
21. Nosek L, Heinemann L, Kaiser M, Arnolds S, Heise T. No increase in the duration of action with rising doses of insulin aspart. Diabetes 2003; 52: A128.
22. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990; 28: 72-78.
23. Rave K, Nosek L, Heinemann L et al. Dependency of the metabolic effect of sc-injected human regular insulin on intra-abdominal fat in patients with type 2 diabetes. Horm Metab Res 2004; 36: 307-311.
24. Heise T, Nosek L, Spitzer H et al. Insulin glulisine: A faster onset of action compared with insulin lispro. Diabetes Obes Metab 2007; 9: 746-753.
25. ADA. Insulin administration. Diabetes Care 2003; 26: S121-S124.
26. Glulisine I, Apidra prescribing information. 2006. http://products.sanofi-aventis.us/apidra/apidra.html.
27. Burge MR, Castillo KR, Schade DS. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM. Diabetes Care 1997; 20: 152-155.
28. Strachan MW, Frier BM. Optimal time of administration of insulin lispro. Importance of meal composition. Diabetes Care 1998; 21: 26-31.
29. Howey DC, Bowsher RR, Brunelle RL et al. [Lys(B28), Pro(B29)]-human insulin: Effect of injection time on postprandial glycemia. Clin Pharmacol Ther 1995; 58: 459-469.
30. Frohnauer MK, Woodworth JR, Anderson JH. Graphical human insulin time-activity profiles using standardized definitions. Diabetes Technol Ther 2001; 3: 419-429.